Corrigendum to “Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway” [Canc. Lett. 342 (2014) 150–158](S0304383513006393)(10.1016/j.canlet.2013.08.042);Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway

Cancer Letters

Volumn 342, Issue 1, 2014, Pages 150-158

  Zhao, Zhiqiang ^a   Wu, Man si ^b   Zou, Changye ^a   Tang, Qinglian ^a   Lu, Jinchang ^a   Liu, Dawei ^a   Wu, Yuanzhong ^b   Yin, Junqiang ^a   Xie, Xianbiao ^a   Shen, Jingnan ^a   Kang, Tiebang ^b   Wang, Jin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CHC; MCT1; NF B pathway; Osteosarcoma

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCARBOXYLATE TRANSPORTER 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; GLYCOLYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TUMOR GROWTH;

EID: 84887607569     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.09.019     Document Type: Erratum

References (39)

1. Biermann J.S., Adkins D., Benjamin R., Brigman B., Chow W., Conrad E.U., Frassica D., Frassica F.J., George S., Healey J.H., Heck R., Letson G.D., Mayerson J., McGarry S.V., O'Donnell R.J., Patt J., Randall R.L., Santana V., Satcher R.L., Schmidt R.G., Siegel H.J., Wong M.K., Yasko A.W. Bone cancer. Journal of the National Comprehensive Cancer Network: JNCCN 2007, 5:420-437.
2. Bulut G., Hong S.H., Chen K., Beauchamp E.M., Rahim S., Kosturko G.W., Glasgow E., Dakshanamurthy S., Lee H.S., Daar I., Toretsky J.A., Khanna C., Uren A. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene 2012, 31:269-281.
3. Schwartz C.L., Gorlick R., Teot L., Krailo M., Chen Z., Goorin A., Grier H.E., Bernstein M.L., Meyers P. Multiple drug resistance in osteogenic sarcoma: INT0133 from the children's oncology group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2007, 25:2057-2062.
4. Ferrari S., Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Current Opinion in Oncology 2007, 19:341-346.
5. Zhang P., Yang Y., Zweidler-McKay P.A., Hughes D.P. Critical role of notch signaling in osteosarcoma invasion and metastasis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2008, 14:2962-2969.
6. Susa M., Iyer A.K., Ryu K., Choy E., Hornicek F.J., Mankin H., Milane L., Amiji M.M., Duan Z. Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma. PloS One 2010, 5:e10764.
7. Fantin V.R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9:425-434.
8. Warburg O. On respiratory impairment in cancer cells. Science (New York, NY) 1956, 124:269-270.
9. Gallagher S.M., Castorino J.J., Wang D., Philp N.J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Research 2007, 67:4182-4189.
10. Pinheiro C., Reis R.M., Ricardo S., Longatto-Filho A., Schmitt F., Baltazar F. Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. Journal of Biomedicine & Biotechnology 2010, 2010:427694.
11. Halestrap A.P., Meredith D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Archiv: European Journal of Physiology 2004, 447:619-628.
12. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 2009, 92:329-333.
13. Semenza G.L. Tumor metabolism: cancer cells give and take lactate. The Journal of Clinical Investigation 2008, 118:3835-3837.
14. Kirk P., Wilson M.C., Heddle C., Brown M.H., Barclay A.N., Halestrap A.P. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. The EMBO Journal 2000, 19:3896-3904.
15. Le Floch R., Chiche J., Marchiq I., Naiken T., Ilk K., Murray C.M., Critchlow S.E., Roux D., Simon M.P., Pouyssegur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:16663-16668.
16. Chen X., Lin J., Kanekura T., Su J., Lin W., Xie H., Wu Y., Li J., Chen M., Chang J. A small interfering CD147-targeting RNA inhibited the proliferation, invasiveness, and metastatic activity of malignant melanoma. Cancer Research 2006, 66:11323-11330.
17. Sonveaux P., Vegran F., Schroeder T., Wergin M.C., Verrax J., Rabbani Z.N., De Saedeleer C.J., Kennedy K.M., Diepart C., Jordan B.F., Kelley M.J., Gallez B., Wahl M.L., Feron O., Dewhirst M.W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation 2008, 118:3930-3942.
18. Mathupala S.P., Parajuli P., Sloan A.E. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 2004, 55:1410-1419. [discussion 1419].
19. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
20. Kim H.J., Hawke N., Baldwin A.S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death and Differentiation 2006, 13:738-747.
21. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Reviews Cancer 2002, 2:301-310.
22. Johnson R.F., Witzel, Perkins N.D. p53-Dependent regulation of mitochondrial energy production by the RelA subunit of NF-kappaB. Cancer Research 2011, 71:5588-5597.
23. Mauro C., Leow S.C., Anso E., Rocha S., Thotakura A.K., Tornatore L., Moretti M., De Smaele E., Beg A.A., Tergaonkar V., Chandel N.S., Franzoso G. NF-kappaB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nature Cell Biology 2011, 13:1272-1279.
24. Wang C.Y., Mayo M.W., Baldwin A.S. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (New York, NY) 1996, 274:784-787.
25. Yin J.Q., Shen J.N., Su W.W., Wang J., Huang G., Jin S., Guo Q.C., Zou C.Y., Li H.M., Li F.B. Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacologica Sinica 2007, 28:712-720.
26. Deng J., Miller S.A., Wang H.Y., Xia W., Wen Y., Zhou B.P., Li Y., Lin S.Y., Hung M.C. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002, 2:323-334.
27. Lv X.B., Xie F., Hu K., Wu Y., Cao L.L., Han X., Sang Y., Zeng Y.X., Kang T. Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1. The Journal of Biological Chemistry 2010, 285:18234-18240.
28. Liang Y., Zhong Z., Huang Y., Deng W., Cao J., Tsao G., Liu Q., Pei D., Kang T., Zeng Y.X. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. The Journal of Biological Chemistry 2010, 285:4931-4940.
29. Berlin O., Samid D., Donthineni-Rao R., Akeson W., Amiel D., Woods V.L. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Research 1993, 53:4890-4895.
30. Pinheiro C., Albergaria A., Paredes J., Sousa B., Dufloth R., Vieira D., Schmitt F., Baltazar F. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 2010, 56:860-867.
31. Pinheiro C., Longatto-Filho A., Scapulatempo C., Ferreira L., Martins S., Pellerin L., Rodrigues M., Alves V.A., Schmitt F., Baltazar F. Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Archiv: An International Journal of Pathology 2008, 452:139-146.
32. Pinheiro C., Longatto-Filho A., Pereira S.M., Etlinger D., Moreira M.A., Jube L.F., Queiroz G.S., Schmitt F., Baltazar F. Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Disease Markers 2009, 26:97-103.
33. Fang J., Quinones Q.J., Holman T.L., Morowitz M.J., Wang Q., Zhao H., Sivo F., Maris J.M., Wahl M.L. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Molecular Pharmacology 2006, 70:2108-2115.
34. Koukourakis M.I., Giatromanolaki A., Harris A.L., Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Research 2006, 66:632-637.
35. Zou C.Y., Wang J., Shen J.N., Huang G., Jin S., Yin J.Q., Guo Q.C., Li H.M., Luo L., Zhang M., Zhang L.J. Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacologica Sinica 2008, 29:325-332.
36. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
37. Vegran F., Boidot R., Michiels C., Sonveaux P., Feron O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Research 2011, 71:2550-2560.
38. Wang C.Y., Cusack J.C., Liu R., Baldwin A.S. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Medicine 1999, 5:412-417.
39. Dai Y., Lawrence T.S., Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. American Journal of Translational Research 2009, 1:1-15.